Skriv ut
Kategori: Nyheter

IHE

Institutet för Hälso- och Sjukvårdsekonomi 

värd för konferensen Mount Hood Diabetes Challenge

IHE kommer att vara värd för Internationella komnferensen Mount Hood 2022 Diabetes Challenge som arrangeras den 24 september i Malmö. 

Mount Hood Diabetes Challenge Network är en diabetesspecifik hälsoekonomisk konferens för personer som arbetar med hälsoekonomiska modeller inom diabetesområdet.

Det kommer diskuteras

• struktur,

• teknik och

• utfall för olika hälsoekonomiska modeller samt

• hur man hanterar diabetesrelaterade komplikationer och osäkerhet.

 

Mer info om konferensen

https://www.mthooddiabeteschallenge.com/conference?utm_campaign=cmp_2931257&utm_source=getanewsletter&utm_medium=email

Ekonomisk modellering inom diabetes och fetma

https://ihe.se/var-expertis/ekonomisk-modellering-inom-diabetes-och-fetma/?utm_campaign=cmp_2931257&utm_source=getanewsletter&utm_medium=email

Competence 

IHE has considerable experience in cutting edge research on the economics of obesity and diabetes, including more than 50 peer-reviewed publications and 60 podium and poster presentations.

IHE works with health authorities, life science companies, and academia on projects ranging from developing national treatment guidelines to estimating future disease burden and from early stage decision-making to market access.

IHE staff:

      • Have developed two internationally established and validated economic models of Type 2 diabetes, which have been accepted by HTA authorities in Sweden, Norway, U.K., Canada, Scotland, Ireland, and Australia
      • Have developed an economic micro-simulation model of Type 1 diabetes, which has been used for the Swedish Dental and Pharmaceutical Benefits Agency (TLV) for decision-making, among others
      • Have collaborated successfully with life science companies to obtain market access in European and North American countries
      • Have been commissioned by the National Board of Health and Welfare in Sweden to assist with development of diabetes treatment guidelines
      • Supervise doctoral students at Lund University and Karolinska Institute, perform peer review, and participate in diabetes-related advisory boards as health economics experts
      • Serve on the executive committee of biennial Mt. Hood Diabetes Modelling Challenge Network

Special areas of competence include 

      • Economic modelling and market access support
      • Model development
      • Analysis of registry data and real-world evidence
      • Literature review
      • Patient preferences and Willingness-to-Pay

IHE and Economic Modelling of Diabetes

https://ihe.se/en/our-expertise/economic-modelling-in-diabetes-and-obesity/economic-modelling-of-diabetes/
 

Economic Models by IHE

IHE has developed and validated two economic models of Type 2 diabetes, which have been accepted by HTA authorities around the globe including Sweden, Norway, U.K., Canada, Scotland, Ireland, and Australia:

  • • The Economic and Health Outcomes models of Type 2 diabetes Mellitus(ECHO-T2DM) is a comprehensive, flexible micro-simulation model with 1st and 2nd order uncertainty which has participated in the past 5 Mount Hood Diabetes Challenge Congresses
  • • The IHE Diabetes Cohort Model(IHE-DCM) is a simpler and faster cohort simulation model of Type 2 diabetes, also including 2nd order uncertainty which can be licensed to clients who wish to set up and run a wide range of different scenarios themselves
  • • A recently published cross-validation studyillustrates that there was little evidence that estimated cost-effectiveness metrics, the outcomes that matter most to stakeholders, differed systematically between IHE-DCM and ECHO-T2DM

IHE has also developed an economic micro-simulation model of Type 1 diabetes(ECHO-T1DM), which has been used for the Swedish Dental and Pharmaceutical Benefits Agency (TLV) for decision-making, among others.

IHE has also developed and validated an economic model of diabetic kidney disease (DKD) based on the results of the landmark CREDENCE renal outcomes study, the CREDENCE Economic Model of DKD (CREDEM-DKD), a Discrete Event Simulation (DES) micro-simulation model including key renal and CV outcomes.

Publications and Presentations

Read more about peer-reviewed publicationspodium presentations and poster presentations in the area of diabetes

https://ihe.se/en/our-expertise/economic-modelling-in-diabetes-and-obesity/economic-modelling-of-diabetes/ihe-models-podium-presentations/

Podium Presentations

  1. Willis M, Neslusan C, Nilsson A, Asseburg C. Diabetic Kidney Disease (DKD) and Renal Protection in T2DM: An Underappreciated Driver of C-E in Economic Evaluation? Presented at 9th Mt Hood Diabetes Challenge Network Meeting, Dusseldorf, Germany, 6-7 October. 2018.
  2. Willis M, Asseburg C, Nilsson A. Challenges and Opportunities Associated with Modeling Cardioprotection in Economic Evaluation: Some Initial Reflections – Presented at 9th Mt Hood Diabetes Challenge Network Meeting, Dusseldorf, Germany, 6-7 October. 2018.
  3. Willis M, Neslusan C, Johansen P, Nilsson A, Asseburg C, Schroeder M. The Economic Consequences of Clinical Inertia in Treatment Intensification for Type 2 Diabetes Mellitus (T2DM) in the UK. Podium presentation at EASD 51st Annual Meeting. Stockholm, Sweden 2015.
  4. Willis M, Neslusan C, He J. Implications of Key Biomarker Trends on Health Outcomes in Patients with Type 2 Diabetes Mellitus (T2DM) in the US Podium presentation at ADA 72nd Scientific Sessions. Philadelphia, Pennsylvania, USA 2012.
  5. Willis M, Neslusan C, Asseburg C, He J. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). Podium presentation at ADA 71st Scientific Sessions. San Diego, CA, USA 2011.
  6. Willis M, Asseburg C, He J, Neslusan C. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). Podium presentation at iHEA World Congress. Toronto, Canada 2011.
  7. Willis M, Asseburg C, Neslusan C, He J. The Economic Importance of Metabolic Memory in the Treatment of Type 2 Diabetes Mellitus (T2DM). Podium presentation at ADA 70th Scientific Sessions. Orlando, Florida, USA 2010.
  8. Willis M, Asseburg C, He J, Neslusan C. The Cost-Effectiveness of “Getting-to Goal” in Patients with Newly Diagnosed Type 2 Diabetes Podium presentation at ADA 69th Scientific Sessions New Orleans, Louisiana, USA 2009.
  9. Willis M, Asseburg C, Neslusan C, Persson U. The Cost-Effectiveness of the Early Insulin Use Treatment Pathway in the ADA/EASD Joint Consensus Algorithm for the Treatment of Type 2 Diabetes. Podium presentation at ADA 68th Scientific Sessions. San Francisco, CA, USA 2008.
  10. Willis M, Neslusan C. Opportunities to Use Economic Modeling for Internal Pharma Decision-Making in T2DM. Podium presentation at iHEA 6th World Congress. Copenhagen, Denmark 2007.

Poster Presentations

  1. Willis M, Durkin M, Neslusan C, Traina S, Nilsson A. Estimated Renal and Cardiovascular Outcomes and Cost Offsets in Patients with Type 2 Diabetes (T2D) and Diabetic Nephropathy (DKD) Treated with Canagliflozin. Poster presentation at ISPOR 25th Annual International Meeting (Virtual meeting) 2020.
  2. Liu A, Bech PG, Fridhammar A, Nilsson A, Willis M, Nuhoho S. Cost Effectiveness of Oral  Semaglutide 14 mg vs Empagliflozin 25 mg in Canada. Poster presentation at ADA 80th meeting. virtual meeting 2020.
  3. Willis M, Neslusan C, Nilsson A, Asseburg C. Assessing the Value of Canagliflozin Versus Sitagliptin as Second-Line Therapy in the United States: The Importance of Considering Evidence from the CANVAS Program. Poster presentation at 78th ADA Orlando, USA 2018.
  4. Nilsson A, Willis M, Neslusan C. A Review of the Costs of Lower-extremity Amputations in Patients with Diabetes in the United States. Poster presentation at ISPOR 23rd Annual International Meeting. Baltimore, MD, USA 2018.
  5. Garcia-Sanchez J, Willis M, Nilsson A, Ericson O, Ball P. Estimated events avoided and cost offsets associated with using canagliflozin to treat T2DM patients with high risk of or established cardiovascular disease (CVD) in England. Poster presentation at ISPOR 21th European Annual Meeting. Barcelona, Spain 2018.
  6. Willis M, Neslusan C, Johansen P, Nilsson A. The Importance of Considering the Evolving Evidence Base on Cardiovascular Effects of Anti-Hyperglycemic Agents on Estimates of ‘Value for Money’. Poster presentation at 77th ADA San Diego, USA 2017.
  7. Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, et al. Time Until Insulin Initiation for Canagliflozin Versus Dapagliflozin and Empagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus in the UK. Poster presentation at ISPOR 21st Annual International Meeting. Washington DC, USA 2016.
  8. Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, et al. Time Until Insulin Initiation for Canagliflozin Versus Sitagliptin in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus in the UK. Poster presentation at ADA 76th Scientific Sessions. New Orleans, LA, USA 2016.
  9. Neslusan C, Willis M, Johansen P, Schroeder M, Nilsson A, Chan E, et al. The Role of Estimated Glomerular Filtration Rate in Cost-Effectiveness Analyses Using Canagliflozin vs Sulfonylurea to Treat Type 2 Diabetes Mellitus. Poster presentation at ADA 76th Scientific Sessions. New Orleans, LA, USA 2016.
  10. Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M. Update of the Model Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Poster Presentation at ISPOR 21st Annual International Meeting. Washington DC, USA 2016.
  11. Willis M, Neslusan C, Martin S, Johansen P, Asseburg C, O’Brien D. Threshold-Based Metrics may not Value all Benefits of Improved HbA1c: Implications for Health Care Resource Allocation. Poster presentation at International Diabetes Federation – World Diabetes Congress. Vancouver, Canada 2015.
  12. Willis M, Johansen P, Neslusan C. The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.
  13. Teschemaker A, Neslusan C, Sabapathy S, Yoong K, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin Versus Saxagliptin Among Older Individuals Living with Type 2 Diabetes Mellitus in Canadas. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.
  14. Schroeder M, Johansen P, Willis M, Neslusan C. The Cost-Effectiveness of Canagliflozin Versus Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes Mellitus as Monotherapy in the United Kingdom. Poster presentation at ISPOR 18th European Annual Meeting. Milan, Italy 2015.
  15. Schroeder M, Johansen P, Willis M, Neslusan C. The Cost-Effectiveness of Canagliflozin Versus Sulphonylurea in Patients with Type 2 Diabetes With inadequate Control on Metformin Monotherapy in the United Kingdom. Poster presentation at Diabetes UK Professional Conference, London, U.K 2015.
  16. Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. Impact of Weight-related Utilities on the Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-line Therapy in Type 2 Diabetes Mellitus in a Canadian Setting. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.
  17. Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea in a Canadian Setting. Poster presentation at ISPOR 20th Annual Meeting Philadelphia, Pennsylvania, USA 2015.
  18. Pititto L, Neslusan C, Teschemaker A, Johansen P, Willis M, Asano E, et al. Cost-effectiveness of Canagliflozin Versus Sitagliptin as Add-on to Metformin Plus Sulfonylurea in Patients with Type 2 Diabetes Mellitus in Brazil. Poster presentation at ISPOR 5th Latin America Conference Santiago, Chile 2015.
  19. Bacon T, Willis M, Johansen P, Neslusan C. Time Until Insulin Initiation for Canagliflozin Versus Dapagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus in Ireland. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.
  20. Yoong K, Willis M, Johansen P, Yim C, Teschemaker A, Neslusan C. The Impact of Alternative Estimates of Disutilities Associated with Hypoglycemia on Net QALYs: Canagliflozin versus Sitagliptin as Add-On Therapy in Individuals with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on a Background of Metformin (MET) plus Sulfonylurea (SU) in the Canadian Setting. Poster presentation at ISPOR 19th Annual International Meeting. Montreal, QC, Canada 2014.
  21. Thompson G, Schroeder M, Neslusan C, Willis M, Johansen P, Teschemaker A. The Cost-Effectiveness of Canagliflozin (CANA) versus Sitagliptin (SITA) as Third-Line Therapy in the Treatment of Type 2 Diabetes Mellitus in the U.K. Poster presentation at EASD 50th Annual Meeting. Stockholm, Sweden 2014.
  22. Schroeder M, Johansen P, Thompson G, Neslusan C, Willis M. The Cost-Effectiveness of Canagliflozin Versus Dapagliflozin in Patients with Type 2 Diabetes Mellitus with Inadequate Control on metformin Monotherapy in the United Kingdom. Poster presentation at ISPOR 17th Annual European Congress Amsterdam, Netherlands 2014.
  23. Neslusan C, Teschemaker A, Martin S, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin (CANA) Versus Dapagliflozin (DAPA) as an Add-On to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States. Poster presentation at ISPOR 19th Annual International Meeting. Montreal, QC, Canada 2014.
  24. Neslusan C, Martin S, Teschemaker A, Vo L, Johansen P, Willis M. Cost-effectiveness Analysis of Canagliflozin Versus Maximally Titrated Glimepiride as an Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in the United States. Poster presentation at ADA 74th Scientific Sessions. San Francisco, CA, USA 2014.
  25. Martin S, Neslusan C, Vo L, Teschemaker A, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin (CANA) Versus Sitagliptin (SITA) as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US. Poster presentation at ADA 74th Scientific Sessions. San Francisco, CA, USA 2014.
  26. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. The Cost-Effectiveness of Canagliflozin Versus Liraglutide in Patients with Type 2 Diabetes Failing to Achieve Glycaemic Control on Metformin Monotherapy in Ireland. Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands 2014.
  27. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. The Cost-Effectiveness of Canagliflozin Versus Insulin Secretagogues (Sulphonylureas) or Insulin in Patients with Type 2 Diabetes Mellitus as Add-on to Metformin in Ireland. Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands 2014.
  28. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of type 2 Diabetes Mellitus Therapy in Ireland? Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands2014.
  29. Willis M, Johansen P, Schroeder M, Thompson G, Girod I, Neslusan C. Sources of Long-term Quality Adjusted Life (QALY) Gains for Canagliflozin (CANA) versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.
  30. Thompson G, Willis M, Johansen P, Neslusan C, Schroeder M, Girod I. Assessment of the Key Drivers of the Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress, Dublin, Ireland 2013.
  31. Schroeder M, Willis M, Johansen P, Girod I, Neslusan C, Thompson G. Impact of Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.
  32. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia A, Puig A. A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Dual Therapy in Mexico. Poster presentation at ISPOR 4th Latin America Conference. Buenos Aires, Argentina 2013.
  33. Neslusan C, Johansen P, Willis M, Martin S. A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Monotherapy in the United States. Poster presentation at ADA 73rd Scientific Sessions. Chicago, IL, USA 2013.
  34. Girod I, Willis M, Johansen P, Schroeder M, Thompson G, Neslusan C. Sources of Long-term Quality Adjusted Life (QALY) Gains for Canagliflozin (CANA) versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.
  35. Willis M, He J, Neslusan C, Johansen P, Worbes-Cerezo M. The Importance of HbA1c Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 15th Annual European Congress. Berlin, Germany 2012.
  36. Teschemaker A, Johansen P, Brazier N, Neslusan C, Willis M. The Health Impact of Getting to Glucose, Systolic Blood Pressure (SBP), and Serum Cholesterol Goals in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada. Poster presentation at CDA/CSEM Professional Conference and Annual Meetings. Vancouver, Canada 2012.
  37. Johansen P, Teschemaker A, Brazier N, Neslusan C, Willis M. Effect of Modest Weight Loss on Long-term Health Outcomes in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada. Poster presentation at CDA/CSEM Professional Conference and Annual Meetings. Vancouver, Canada 2012.
  38. Willis M, Neslusan C, He J, Worbes-Cerezo M. The Economic Impact of Weight Loss in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger than 50 in Sweden. Poster presentation at ISPOR 14th Annual European Congress. Madrid, Spain 2011.
  39. He J, Neslusan C, Willis M, Worbes-Cerezo M. The Cost-Effectiveness of getting to Glucose, Blood Pressure, and Lipid Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden. Poster presentation at ISPOR 14th Annual European Congress. Madrid, Spain 2011.
  40. Willis M, He J, Neslusan C, Chievic E. The Economic Importance of Metabolic Memory in the Treatment of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 13th Annual European Congress. Prague, Czech Republic 2010.
  41. Willis M, Asseburg C, Neslusan C, He J, Ingham M. The Economic Impact of Weight Loss for Patients with Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in the US. Poster presentation at ISPOR 15th Annual Meeting. Atlanta, GA, USA 2010.
  42. He J, Willis M, Asseburg C, Neslusan C, Persson U. Simulation of the Chinese Diabetes Treatment Guideline using the IHE/JNJ Diabetes Cost-Effectiveness Model. Poster presentation at World Congress on Health Economics, iHEA. Beijing, China 2009.
  43. Asseburg C, Willis M, Persson U, Neslusan C, He J. Validation of the IHE/JJPS Economic Simulation Model of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 14th Annual Meeting Orlando, Florida, USA 2009.
  44. Willis M, Borg S, Persson U, Neslusan C. Cost-Effectiveness of Sulfonylureas versus Metformin as First-Line Therapy in Newly Diagnosed Type 2 Diabetes. Poster presentation at ADA 67th Scientific Sessions. Chicago, Illinois, USA 2007.
  45. Willis M, Asseburg C, Borg S, Persson U, Neslusan C. Cost-Effectiveness of Strict “Get To Goal” Treatment Directives in the Treatment of Younger Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Poster presentation at ISPOR 9th Annual European Congress. Dublin, Ireland 2007.
Nyhetsinfo
 
Kommentar
Sverige har genom Bengt Jönsson, professor Handelshögskolan i Stockholm och nationelekonom, varit pionjär inom området diabetes-hälsoekonomi. Under åren har flera värdefulla publikation i ämnet skett och området har utvecklats under 25 års tid. Forskare och myndigheter i Sverige och world wide har haft nytta av detta. Ett 10-tal doktorander har disputerat under Bengt Jönssons ledning. Flera av dessa finns nu yrkesverksamma inom IHE.
 
www red DiabetologNytt
Träffar: 192